Simple Summary
Cholangiocarcinoma is an aggressive bile duct cancer with few effective treatments. New drugs are usually tested in mice carrying human tumor cells implanted under the skin, but many drugs that work in these models fail in patients. We compared tumors grown under the skin with tumors grown in the liver, where this cancer naturally arises. Although the tumor cells looked similar under the microscope, the two models differed in gene activity. Only liver-grown tumors showed increased expression of genes of the PI3K–AKT pathway, a signaling route that helps cancer cells grow, adapt their metabolism, and resist treatment. Several of these pathway genes were also increased in human cholangiocarcinoma samples. These findings suggest that liver-implanted mouse models better reflect human disease and may provide a more reliable platform for testing new therapies.
Abstract
Background: Cholangiocarcinoma (CCA) has a poor prognosis, and drugs that are effective in subcutaneous xenograft models frequently fail to show clinical benefit. The role of the implantation site in this translational gap remains unclear. Methods: We established intrahepatic orthotopic and subcutaneous xenograft models using the human SCK CCA cell line in BALB/c nude mice. Tumor development was documented by serial gross observation, and subcutaneous tumor growth was quantified using a caliper. At necropsy, tumors were examined macroscopically and by hematoxylin-and-eosin staining and were subjected to bulk RNA sequencing. Differential expression and gene set enrichment analyses were used to compare signaling and metabolic programs, with cross-reference to The Cancer Genome Atlas-Cholangiocarcinoma (TCGA-CHOL) dataset. Results: Orthotopic tumors formed intrahepatic masses with additional intra-abdominal nodules, whereas subcutaneous xenografts formed localized dorsal masses without dissemination. Tumor cell morphology was comparable. Transcriptomic profiling showed concordant upregulation of cell cycle pathways but divergent metabolic programs—downregulation of cholesterol and sterol metabolism in orthotopic tumors versus downregulation of lipid and fatty acid catabolism in subcutaneous tumors. The phosphatidylinositol 3 kinase–protein kinase B (PI3K–AKT) signaling pathway was enriched only in orthotopic tumors. Eleven PI3K–AKT pathway genes upregulated in orthotopic tumors were also upregulated in human CCA tissues in the TCGA-CHOL dataset. Conclusions: Orthotopic and subcutaneous CCA models differ substantially in microenvironment-shaped transcriptional programs. Selective enrichment of PI3K–AKT pathway genes only in orthotopic tumors may explain the discordance between subcutaneous xenograft drug responses and clinical outcomes. Orthotopic implantation may be a more clinically relevant preclinical model.